Pulmonx Corp Stock Investor Sentiment

LUNG Stock  USD 6.61  0.18  2.65%   
Roughly 76 percent of Pulmonx Corp's stockholders are selling. The analysis of overall sentiment of trading Pulmonx Corp stock suggests that a large number of investors are terrified at this time. The current market sentiment, together with Pulmonx Corp's historical and current headlines, can help investors time the market. In addition, many technical investors use Pulmonx Corp stock news signals to limit their universe of possible portfolio assets.
  

Pulmonx Corp Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Pulmonx Corp can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
2 days ago at news.google.com         
Trading With Integrated Risk Controls - Stock Traders Daily
Google News at Macroaxis
few days ago at news.google.com         
Pulmonx Co. Given Average Recommendation of Moderate Buy by Analysts - MarketBeat
Google News at Macroaxis
few days ago at zacks.com         
Does Pulmonx Have the Potential to Rally 117.74 percent as Wall Street Analysts Expect?
zacks News
few days ago at gurufocus.com         
Pulmonx to Present at the Piper Sandler 36th Annual Healthcare Conference
Gurufocus Stories at Macroaxis
six days ago at businesswire.com         
Pulmonx Partners with American Lung Association to Launch New Educational Initiatives for COPD Patie...
businesswire News
over a week ago at gurufocus.com         
FMR LLC Bolsters Stake in Pulmonx Corp
Gurufocus Stories at Macroaxis
over a week ago at news.google.com         
FMR LLC Bolsters Stake in Pulmonx Corp - GuruFocus.com
Google News at Macroaxis
over two weeks ago at gurufocus.com         
Morgan Stanleys Strategic Reduction in Pulmonx Corp Holdings
Gurufocus Stories at Macroaxis
over two weeks ago at finance.yahoo.com         
Pulmonx to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health Services For...
Yahoo News
over two weeks ago at finance.yahoo.com         
TLI Investigators William Stringer MD and Asghar Abbasi PhD, along with Ke Zhang MD of Allerdia Inc....
Yahoo News
over two weeks ago at zacks.com         
Wall Street Analysts Predict an 89.61 percent Upside in Pulmonx Heres What You Should Know
zacks News
over three weeks ago at finance.yahoo.com         
Heres What Analysts Are Forecasting For Pulmonx Corporation After Its Third-Quarter Results
Yahoo News
over three weeks ago at insidermonkey.com         
Pulmonx Corporation Q3 2024 Earnings Call Transcript
insidermonkey News
over three weeks ago at simplywall.st         
Pulmonx Third Quarter 2024 Earnings EPS Beats Expectations
Simply Wall St News at Macroaxis
over three weeks ago at finance.yahoo.com         
Pulmonx Third Quarter 2024 Earnings EPS Beats Expectations
Yahoo News
Far too much social signal, news, headlines, and media speculation about Pulmonx Corp that are available to investors today. That information is available publicly through Pulmonx media outlets and privately through word of mouth or via Pulmonx internal channels. However, regardless of the origin, that massive amount of Pulmonx data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Pulmonx Corp news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Pulmonx Corp relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Pulmonx Corp's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Pulmonx Corp alpha.

Pulmonx Corp Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 1688 shares by David Lehman of Pulmonx Corp at 6.69 subject to Rule 16b-3
09/03/2024
2
Acquisition by Geoffrey Rose of 34500 shares of Pulmonx Corp subject to Rule 16b-3
09/06/2024
3
Disposition of 20000 shares by Glendon French of Pulmonx Corp at 8.09 subject to Rule 16b-3
09/12/2024
4
Disposition of 20000 shares by Glendon French of Pulmonx Corp at 6.52 subject to Rule 16b-3
10/17/2024
5
Pulmonx director sells 130,399 in common stock
10/21/2024
6
Pulmonx Corp Q3 2024 Earnings Revenue Hits 20.4M, EPS at -0.36, Surpassing Estimates
10/30/2024
7
Geneial Secures Major Contract with RENCI and NHLBI to Partner with ARPA-H to Transform Biomedical Data Standardization with Advanced AI
10/31/2024
8
Pulmonx Corporation Q3 2024 Earnings Call Transcript
11/01/2024
9
TLI Investigators William Stringer MD and Asghar Abbasi PhD, along with Ke Zhang MD of Allerdia Inc., receive 2 Million NIHNHLBI Grant to Develop Novel Point-of...
11/06/2024
10
FMR LLC Bolsters Stake in Pulmonx Corp - GuruFocus.com
11/12/2024
11
Pulmonx to Present at the Piper Sandler 36th Annual Healthcare Conference
11/20/2024

Complementary Tools for Pulmonx Stock analysis

When running Pulmonx Corp's price analysis, check to measure Pulmonx Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pulmonx Corp is operating at the current time. Most of Pulmonx Corp's value examination focuses on studying past and present price action to predict the probability of Pulmonx Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pulmonx Corp's price. Additionally, you may evaluate how the addition of Pulmonx Corp to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Equity Valuation
Check real value of public entities based on technical and fundamental data
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
CEOs Directory
Screen CEOs from public companies around the world